These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32524661)

  • 1. Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients.
    Vazquez J; Chavarria M; Lopez GE; Felder MA; Kapur A; Romo Chavez A; Karst N; Barroilhet L; Patankar MS; Stanic AK
    Am J Reprod Immunol; 2020 Sep; 84(3):e13284. PubMed ID: 32524661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries.
    Melichar B; Tousková M; Tosner J; Kopecký O
    Onkologie; 2001 Apr; 24(2):156-60. PubMed ID: 11441296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
    Wei S; Kryczek I; Zou L; Daniel B; Cheng P; Mottram P; Curiel T; Lange A; Zou W
    Cancer Res; 2005 Jun; 65(12):5020-6. PubMed ID: 15958543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of myeloid and lymphoid dendritic cells in peritoneal fluid in women with non-malignant ovarian tumors.
    Wertel I; Kotarski J; Roliński J; Bojarska-Junak A; Gogacz M
    Am J Reprod Immunol; 2003 Sep; 50(3):238-42. PubMed ID: 14629029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the intracellular expression of interleukin 17 in patients with ovarian cancer].
    Rogala E; Nowicka A; Bednarek W; Barczyński B; Wertel I; Zakrzewski M; Kotarski J
    Ginekol Pol; 2012 Jun; 83(6):424-8. PubMed ID: 22880461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
    Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
    Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites.
    Wefers C; Duiveman-de Boer T; Yigit R; Zusterzeel PLM; van Altena AM; Massuger LFAG; De Vries IJM
    Front Immunol; 2018; 9():3156. PubMed ID: 30687337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
    Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
    Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of dendritic cells subsets in peritoneal fluid].
    Błaszkowska I; Roliński J; Gogacz M; Kotarski J
    Ginekol Pol; 2001 Dec; 72(12A):1455-9. PubMed ID: 11883296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
    Ma YX; Ye F; Chen HZ; Lü WG; Xie X
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):734-9. PubMed ID: 17565840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies.
    Chen CK; Wu MY; Chao KH; Ho HN; Sheu BC; Huang SC
    J Formos Med Assoc; 1999 Jan; 98(1):24-30. PubMed ID: 10063270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
    Liu M; Xie J; Zhao S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
    Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
    Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
    Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
    Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
    Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Wyss T; Inoges S; de Vries IJM; Dartiguenave F; Jichlinski P; Derrè L; Coukos G; Melero I; Harari A; Romero P; Viganó S; Kandalaft LE
    Eur J Cancer; 2020 Aug; 135():173-182. PubMed ID: 32590296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.
    Melichar B; Savary C; Kudelka AP; Verschraegen C; Kavanagh JJ; Edwards CL; Platsoucas CD; Freedman RS
    Clin Cancer Res; 1998 Mar; 4(3):799-809. PubMed ID: 9533550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.